Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCVS Group Regulatory News (CVSG)

Share Price Information for CVS Group (CVSG)

Share Price is delayed by 15 minutes
Get Live Data
1,197.00    -18.00 (-1.48%)
Bid:
1,198.00
Ask:
1,200.00
Spread: 2.00 (0.167%)
Market Cap: £832.43m
CVSG Live PriceLast checked at - London Stock Exchange

Intraday CVS Group Share Chart

Non-Executive Director Changes

25 Mar 2026 07:00

RNS Number : 9811X
CVS Group plc
25 March 2026
 

For Immediate Release 25 March 2026

CVS Group plc

("CVS", the "Company" or the "Group")

 

Non-Executive Director Changes

 

CVS, the UK listed veterinary group and a leading provider of veterinary services, is pleased to announce the appointment of Helen Keays and Jane Bednall as Independent Non-Executive Directors with effect from 1 April 2026, the retirement of Deborah Kemp with effect from 30 June 2026 and a change in Chair of the Group's Nomination Committee.

 

Retirement of Deborah Kemp

Deborah Kemp, who joined the board in January 2018 and who is presently Senior Independent Director and Chair of the Remuneration Committee will retire and step down from the Board and all board committees on 30 June 2026.

 

Appointment of Helen Keays

Helen Keays is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at Nichols plc following an executive career in consumer-facing multi-site businesses across retail, mobile telecommunications and retail financial services. Helen has worked at Vodafone plc, latterly as General Manager of Singlepoint, and previously at Sears plc. Helen has previously been an Independent Non-Executive Director of The Restaurant Group, Domino's Pizza UK & Ireland, Communisis plc, Majestic Wine plc, Mattioli Woods plc and Chrysalis Group plc. Helen is an experienced Non-Executive Director and Remuneration Committee Chair and will add value to the board through her expertise in people development, consumer marketing and CRM.

 

From the date of her appointment, Helen Keays will become Chair Designate of the Remuneration Committee and will also become a member of the Group's Audit and Risk Committee and Nomination Committee. Helen will formally become Chair of the Remuneration Committee with effect from 1 July 2026.

 

Appointment of Jane Bednall

Jane Bednall is presently an Independent Non-Executive Director of Fuller Smith & Turner plc and Independent Non-Executive Director and Chair of the Remuneration, People and Culture Committee for The Kings Cross Group, appointed on behalf of AustralianSuper, Australia's largest pension fund. This follows an executive career in senior leadership roles at British Airways, InterContinental Hotel Group (IHG), Centrica and most recently SSE plc where she was Chief Marketing Officer and formerly Managing Director of Retail Energy. Jane was previously Non-Executive Director of DFS plc, EI Group plc and Smart Energy GB. Jane will add value to the board through her experience in multi-site retail and leisure businesses and her expertise in branding, consumer behaviour and insights.

 

From the date of her appointment, Jane will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee.

 

Change in Nomination Committee Chair

David Wilton, Chair of CVS, will succeed Richard Gray as Chair of the Nominations Committee with effect from 1 April 2026.

 

David Wilton, CVS Chair commented:

 

"On behalf of the board, I am delighted to welcome Helen Keays and Jane Bednall to CVS and I look forward to working with them. Helen and Jane will strengthen the board through their extensive knowledge and experience in developing consumer propositions and in marketing across a range of client facing businesses.

 

"I would also like to record my profound thanks to Deborah Kemp for her support and for the significant contribution she has made to CVS over the past nine years. Deborah joined the Board in January 2018 as Non-Executive Director and has served as Senior Independent Director, Remuneration Committee Chair, Employee Engagement Director and, for a period of six months, Interim Chair. Deborah has played an important governance role in support of the Group's considerable expansion and will be missed."

 

The Company confirms that there is no further information about Helen Keays or Jane Bednall requiring disclosure under paragraphs 6.4.8R (1) to (6) of the FCA UK Listing Rules.

 

ENDS

 

Contacts

CVS Group plc via Camarco

Richard Fairman, Chief Executive Officer

Scott Morrison, Group Legal Counsel and Company Secretary

 

Camarco (Financial PR)

Ginny Pulbrook cvsg@camarco.co.uk

Tilly Butcher +44 (0)20 3757 4980

Letaba Rimell

 

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

 

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASEAEFLEMSESD
Date   Source Headline
19th Jan 20242:24 pmRNSExercise of SAYE Options and PDMR Dealing
12th Jan 20241:56 pmRNSExercise of SAYE Options and PDMR Dealing
12th Jan 20247:00 amRNSBlock Listing Interim Review
5th Jan 20242:44 pmRNSReplacement of Director/PDMR Shareholding
5th Jan 202410:25 amRNSDirector/PDMR Shareholding
29th Dec 20237:00 amRNSExercise of Options and Total Voting Rights
22nd Dec 20237:48 amRNSBlock Listing Application
30th Nov 20237:00 amRNSExercise of Options and Total Voting Rights
29th Nov 20233:43 pmRNSResult of AGM
29th Nov 20237:00 amRNSAGM Statement and Trading Update
24th Nov 20233:56 pmRNSGrant of Options under CVS Group plc
3rd Nov 20237:05 amRNSPosting of Annual Report and Notice of AGM
31st Oct 20234:46 pmRNSExercise of Options and Total Voting Rights
27th Oct 20237:00 amRNSDirectorate Change
13th Oct 20235:21 pmRNSConfirmation of dividend dates
9th Oct 20232:58 pmRNSExercise of Options, PDMR Dealing, EBT and TVR
29th Sep 20237:00 amRNSExercise of Options and Total Voting Rights
21st Sep 20237:00 amRNSFinal results for the year ended 30 June 2023
7th Sep 202310:50 amRNSResponse to CMA review into veterinary market
31st Aug 20237:00 amRNSExercise of Options and Total Voting Rights
31st Jul 20237:00 amRNSTotal Voting Rights
27th Jul 20237:00 amRNSTrading update, AU expansion and UK acquisitions
12th Jul 20237:00 amRNSBlock Listing Interim Review and TVR Update
30th Jun 20237:00 amRNSExercise of Options and Total Voting Rights
22nd Jun 20237:00 amRNSDirectorate Change
31st May 20237:00 amRNSExercise of Options and Total Voting Rights
12th May 20234:41 pmRNSStandard form for notification of major holdings
5th May 20238:53 amRNSBlock Listing Application
2nd May 20237:00 amRNSTotal Voting Rights
31st Mar 20231:39 pmRNSHolding(s) in Company
31st Mar 20237:00 amRNSTotal Voting Rights
10th Mar 202310:37 amRNSExercise of SAYE Options, PDMR Dealing and TVR
28th Feb 20237:00 amRNSExercise of Options and Total Voting Rights
24th Feb 20237:00 amRNSInterim Results
2nd Feb 20234:42 pmRNSExercise of Options and Total Voting Rights
26th Jan 20237:00 amRNSHalf year Trading Update
11th Jan 20234:31 pmRNSBlock Listing Interim Review and TVR Update
10th Jan 202312:24 pmRNSExercise of SAYE Options and PDMR Dealing
30th Dec 20227:00 amRNSExercise of Options and Total Voting Rights
20th Dec 20224:38 pmRNSExercise of Options and PDMR Dealing
30th Nov 20227:00 amRNSExercise of Options and Total Voting Rights
25th Nov 20224:22 pmRNSSAYE Option Scheme & PDMR Dealing
23rd Nov 20222:31 pmRNSResult of AGM
23rd Nov 20227:00 amRNSAGM Statement and Trading Update
8th Nov 20227:00 amRNSCapital Markets Day
31st Oct 20227:00 amRNSExercise of Options and Total Voting Rights
28th Oct 202210:22 amRNSAnnual Report, Notice of AGM & Dividend Timetable
12th Oct 202210:52 amRNSHolding(s) in Company
7th Oct 20227:00 amRNSDirector/PDMR Shareholding
30th Sep 20224:19 pmRNSLong Term Incentive Plan Awards and PDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.